Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Nektar Therapeutics shares valued at $62,802 were sold by Zalevsky Jonathan on Nov 25 ’25. At $54.28 per share, Zalevsky Jonathan sold 1,157 shares. The insider’s holdings dropped to 18,971 shares worth approximately $1.1 million following the completion of this transaction.
Also, Wilson Mark Andrew sold 630 shares, netting a total of over 34,196 in proceeds. Following the sale of shares at $54.28 each, the insider now holds 21,585 shares.
Before that, ROBIN HOWARD W had sold 2,207 shares from its account. In a trade valued at $119,796, the President & CEO traded Nektar Therapeutics shares for $54.28 each. Upon closing the transaction, the insider’s holdings decreased to 2,207 shares, worth approximately $3.13 million.
As published in their initiating research note from Citigroup on November 26, 2025, Nektar Therapeutics [NKTR] has been a Buy and the price target has been revised to $102. Analysts at H.C. Wainwright resumed the stock at ‘”a Buy”‘ outlook in a report released in late June. As of June 24, 2025, BTIG Research has reiterated its “Buy” rating for NKTR. Earlier on April 11, 2025, Jefferies upgraded its rating. Their new recommendation was “a Buy” for NKTR stock which previously was a “a Hold”.
Analyzing NKTR Stock Performance
On last trading session, Nektar Therapeutics [NASDAQ: NKTR] plunged -1.77% to $57.74. The stock’s lowest price that day was $56.76, but it reached a high of $58.99 in the same session. During the last five days, there has been a surge of approximately 1.07%. Over the course of the year, Nektar Therapeutics shares have jumped approximately 277.39%. Shares of the company reached a 52-week high of $66.92 on 10/31/25 and a 52-week low of $6.45 on 04/09/25.
Support And Resistance Levels for Nektar Therapeutics (NKTR)
According to the 24-hour chart, there is a support level at 56.63, which, if violated, would cause prices to drop to 55.52. In the upper region, resistance lies at 58.92. The next price resistance is at 60.10. RSI (Relative Strength Index) is 49.11 on the 14-day chart, showing neutral technical sentiment.
Is Nektar Therapeutics subject to short interest?
Stocks of Nektar Therapeutics saw a sharp rise in short interest on 2025-11-28 jumping by 0.35 million shares to 1.82 million. Data from Yahoo Finance shows that the short interest on 2025-10-31 was 1.47 million shares. A jump of 19.06% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 2.66 of the overall float, the days-to-cover ratio (short ratio) jumped to 2.66.
Which companies own the most shares of Nektar Therapeutics (NKTR)?
In terms of Nektar Therapeutics share price expectations, FactSet research, analysts set an average price target of 121 in the next 12 months, up nearly 105.85% from the previous closing price of $58.78. Analysts anticipate Nektar Therapeutics stock to reach 121 by 2025, with the lowest price target being 121. In spite of this, 3 analysts ranked Nektar Therapeutics stock as Buy at the end of 2025. On March 14, 2025, Oppenheimer assigned a price target of “an Outperform” to the stock and upgraded coverage with a $6.
